Lipin1 and Micro-Dystrophin Gene Therapies for DMD: A New Dual Approach
Official title: Lipin1 and Micro-Dystrophin Gene Therapies for DMD: Independent and Combined Therapeutic Potential
Funded at Wright State University · NIH-11441231 · Data updated 2026-11-12
A study to explore whether boosting Lipin1 together with micro-dystrophin gene therapy could improve muscle and heart health in Duchenne muscular dystrophy patients.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Wright State University NIH-funded |
| Lab location | 1 site (Dayton, United States) |
| Project start | September 15, 2026 |
| Project end | August 31, 2028 |
| Funding year | 2026 |
| Award (this year) | $377,077 |
| NIH project number | 1R21AR088259-01 |
| Project ID | NIH-11441231 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are individuals with Duchenne muscular dystrophy who are eligible for gene-therapy approaches and can participate in studies evaluating muscle and heart effects.
✕Less likely to help
Patients with conditions other than DMD or with contraindications to AAV-based therapies may not benefit.
What this research studies
This project looks at how two potential therapies might work together to help people with Duchenne muscular dystrophy. Researchers plan to use AAV-based delivery to introduce micro-dystrophin and to upregulate Lipin1 in skeletal muscle and heart tissue. The goal is to improve muscle stability, reduce inflammation, and protect heart and lung function, addressing the major causes of death in DMD. The work will involve preclinical testing in muscle and cardiac models to understand safety and potential benefits before moving toward human studies.
Why it matters
Potential benefit: If successful, this dual approach could slow disease progression and improve quality of life for people with DMD by strengthening muscles and protecting heart and respiratory function.
How similar studies have gone: Previous micro-dystrophin approaches show promise, and combining with Lipin1 modulation is a novel strategy with early supportive data.
Where this research is happening
-
Wright State University
Dayton, United States Active
Researchers
- Principal investigator: Ren, Hongmei — Wright State University
- Study coordinator: Ren, Hongmei
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.